Immune checkpoint inhibitors improve the efficacy of neoadjuvant chemotherapy in advanced gastric cancer: a retrospective cohort study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in metastatic gastric cancer. Their potential benefits in the neoadjuvant therapy for advanced gastric cancer (AGC) are promising but require real-world evidence.

Objective

We aimed to assess the real-world impact of adding ICIs to neoadjuvant chemotherapy (NAC) in AGC patients.

Design

This is a retrospective, propensity score-matched analysis of 580 AGC patients treated with NAC, with or without ICIs, followed by radical gastrectomy.

Methods

Patients were matched using propensity score matching (PSM) to balance baseline characteristics. Pathological complete response (pCR) rates and toxicity were compared between the ICIs-Chemo and Chemo cohorts.

Results

After PSM, 188 patients we

SUBMITTER: Chen Y 

PROVIDER: S-EPMC12268129 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature